BiotechTube

irinotecan liposome (II) + temozolomide + fluzoparib

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ewing Sarcoma

Conditions

Ewing Sarcoma

Trial Timeline

Apr 15, 2025 → Feb 1, 2028

NCT ID
NCT06827717

About irinotecan liposome (II) + temozolomide + fluzoparib

irinotecan liposome (II) + temozolomide + fluzoparib is a phase 2 stage product being developed by Sun Pharmaceutical for Ewing Sarcoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06827717. Target conditions include Ewing Sarcoma.

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06827717Phase 2Recruiting

Competing Products

14 competing products in Ewing Sarcoma

See all competitors
ProductCompanyStageHype Score
LinsitinibAstellas PharmaPhase 2
35
Abemaciclib + Irinotecan + TemozolomideEli LillyPhase 2
39
IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab)Eli LillyPhase 2
35
XaluritamigAmgenPhase 1
36
CP-751,871PfizerPhase 1
29
CP-751,871PfizerPhase 1/2
32
Palbociclib + Temozolomide + Irinotecan + Topotecan + CyclophosphamidePfizerPhase 2
39
plerixafor + plerixafor + plerixaforSanofiPhase 1/2
32
regorafenib tabletBayerPhase 1
30
INCB059872IncytePhase 1
18
LurbinectedinJazz PharmaceuticalsPhase 1/2
36
LurbinectedinJazz PharmaceuticalsPhase 1/2
36
CabozantinibExelixisPhase 1
33
INBRX-109 + Irinotecan + Temozolomide + carboplatin + pemetrexed + Leucovorin + FluorouracilInhibrx BiosciencesPhase 1
30